Why almost 80% of my patients are quietly quitting Ozempic

Key issues the physician highlights with Ozempic/GLP-1 medications

1) Most people stop taking it (“quietly quitting”)

Real-world studies cited:

• ~60% stopped within 1 year (2023 cohort; cost not the main barrier)
• ~54% stopped at 1 year, ~72.2% at 2 years (JAMA 2025 cohort; 125,000+ people)
• ~30% drop-off by 3 months and low continuation by 1 year (Blue Cross Blue Shield)

2) Those who stay on it often don’t lose much weight

A repeated pattern is noted: people who achieve less weight loss are more likely to remain on the drug.

3) The drug’s effect fades over time

Key mechanisms described:

• Plateau and diminishing appetite suppression
• Dose titration upward early due to side effects
• Study noted for tirzepatide and semaglutide:
  • Weight falls early, then plateaus as intake rebounds
  • Energy expenditure decreases over time

Why people stop (self-care/behavioral angle)

Loss of food pleasure reduces motivation to continue

The physician describes GLP-1 action as reducing:

• hunger
• the drive to eat
• the pleasure derived from food

Result: social life and celebrations (“beige life”) become less rewarding, so people discontinue.

Quality-of-life gains are minimal—especially for those who lose more weight

• Cited BMJ evidence (quality-of-life comparisons):
  • Weight loss happens, but overall quality-of-life improvements are small
  • Side effects persist
• If people don’t feel better, they stop.

Productivity/wellness strategy implied by the discussion

Don’t rely on medication alone; plan for long-term lifestyle management

The physician contrasts:

• pills/surgery require accepting tradeoffs and consequences
• diet changes are “natural” and adjustable

Practical takeaway (framed as a general wellness approach from the talk):

• If using a medication, pair it with dietary habits you can sustain—because discontinuation often leads to weight regain.
• Have an upfront plan for what “good quality of life” looks like, not just weight change.

Methodology/framework explicitly referenced (evaluation logic)

The physician structures the critique into three main problems:

1. Non-adherence: people stop taking it
2. Limited quality-of-life improvement: especially for those who lose the most weight
3. Diminishing effectiveness over time: weight plateau and reduced ongoing impact

Presenters or sources mentioned

• Physician narrator (unnamed; the speaker in the video)
• STEP 1 trial extension (weight regain when stopping)
• Journal of the American Medical Association (JAMA) 2025 cohort study (~125,000 people)
• Blue Cross Blue Shield study (real-world continuation drop)
• British Medical Journal (BMJ) quality-of-life comparison across obesity drugs
• Obesity journal study, 2024 (tirzepatide vs semaglutide; plateau and intake rebound)